Lokon Pharma AB

“Lokon does not provide investigational drugs to patients outside the clinical trial context. However, for patients who previously responded to a Lokon investigational drug within a clinical trial (as defined in the study protocol), and who may benefit from treatment continuation, the treating physician may request expanded access to the Lokon investigational drug. “Expanded Access” refers to the use of an investigational product outside of a clinical trial, for the potential treatment of a serious or life-threatening condition, and different regulations apply in different countries. Hence, a case-by-case evaluation must be completed prior to an expanded access decision for individual patient use by Lokon Pharma. In the US, an Individual Patient Expanded Access (also referred to as single patient) application can be filed by the treating physician.”